

***Fiscal Year 2024 Department of Defense Glioblastoma Research Program (GBMRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Transformative Consortium Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524GBMRPTCA</p>	<ul style="list-style-type: none"> • Consortium Director <ul style="list-style-type: none"> ○ Independent investigators at or above the level of Assistant Professor (or equivalent) ○ Must commit at least 25% level of effort to direct and manage the consortium and to lead their own project team • Project Team Principal Investigators (PIs) <ul style="list-style-type: none"> ○ Independent investigators at all career levels (or equivalent) 	<ul style="list-style-type: none"> • Supports a multidisciplinary collaborative effort of at least four, but not more than five, distinct yet complementary projects that collectively address a central hypothesis. • Research must address one or more of the FY24 GBMRP areas of emphasis: <ul style="list-style-type: none"> ○ Develop new treatments or advance existing therapies to improve outcomes for glioblastoma patients ○ Identify novel approaches for disease detection and monitoring ○ Expand glioblastoma resources for the research and clinical communities • Supports a Consortium Director and three to four Project Team PIs who jointly lead and execute the proposed research projects, which are integrated into a cohesive strategy that will fundamentally and significantly transform the glioblastoma landscape. • Requires inclusion of a glioblastoma consumer advocate(s) who must be integrated into and play an active role in the leadership and decision-making committees for the consortium. • <i>Submission of a Letter of Intent is required prior to full application submission.</i> • May include clinical or translational research projects and/or clinical trials. • Preliminary data are required. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$9.09 million for total costs. • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): December 23, 2024 5:00 p.m. Eastern time</p> <p>Application: January 13, 2025 11:59 p.m. Eastern time</p>